KRAS and colorectal carcinoma: However, a longstanding clinical challenge has been the heterogeneous response of CRC patients to EGFRi despite wild-type EGFR or KRAS status (Blanke, 2005; Jimeno et al, 2009; Shaib et al, 2013).